Microsatellite instability as a prognostic factor in resected colorectal cancer liver metastases

被引:53
作者
Haddad, R
Ogilvie, RT
Croitoru, M
Muniz, V
Gryfe, R
Pollett, A
Shanmugathasan, P
Fitzgerald, T
Law, CHL
Hanna, SS
Jothy, S
Redston, M
Gallinger, S
Smith, AJ
机构
[1] Sunnybrook & Womens Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada
[2] Univ Toronto, Toronto, ON, Canada
[3] Samuel Lunenfeld Res Inst, Ctr canc Genet, Toronto, ON, Canada
[4] Mt Sinai Hosp, Lab Med & Pathobiol, Toronto, ON M5G 1X5, Canada
关键词
microsatellite instability; colorectal cancer; hepatic metastases; molecular markers;
D O I
10.1245/ASO.2004.03.585
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Two distinct genetic mutational pathways characterized by either chromosomal instability or high-frequency microsatellite instability (MSI-H) are currently recognized in the pathogenesis of colorectal cancer (CRC). Recently, it has been shown that patients with primary CRC that displays MSI-H have a significant, stage-independent, multivariate, survival advantage. Untreated CRC hepatic metastases are incurable and are associated with a median survival of 4 to 12 months. Conversely, surgical resection in selected patients results in a 20% to 50% cure rate. The aim of this study was to investigate the prognostic importance of NISI-H in patients undergoing resection of hepatic CRC metastases. Methods: DNA was extracted from paraffin-embedded, resected metastatic CRC liver lesions and corresponding normal liver parenchyma from 190 patients. MSI-H status was determined by polymerase chain reaction-based evaluation of the noncoding mononucleotide repeats BAT-25 and BAT-26. Results: NISI was detected in tumors from 5 (2.7%) of the 190 CRC patients. All MSI-H tumors were in patients with node-positive CRC primary tumors. The median survival after hepatic resection of MSI-H and non-MSI-H tumors was 67 and 61 months, respectively (P = .9). Conclusions: These data suggest that NISI-H is not a common feature in resected CRC liver metastases and do not suggest a role for MSI in stratifying good versus poor prognosis in these patients.
引用
收藏
页码:977 / 982
页数:6
相关论文
共 30 条
[1]  
Altendorf-Hofmann Annelore, 2003, Surg Oncol Clin N Am, V12, P165, DOI 10.1016/S1055-3207(02)00091-1
[2]  
Boland CR, 1998, CANCER RES, V58, P5248
[3]  
Chen WS, 1997, INT J CANCER, V74, P470, DOI 10.1002/(SICI)1097-0215(19970822)74:4<470::AID-IJC20>3.0.CO
[4]  
2-C
[5]   Cell proliferation-related markers in colorectal liver metastases: Correlation with patient prognosis [J].
Costa, A ;
Doci, R ;
Mochen, C ;
Bignami, P ;
Faranda, A ;
Gennari, L ;
Silvestrini, R .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (05) :2008-2014
[6]   Genetic markers of survival and liver recurrence after resection of liver metastases from colorectal cancer [J].
Crowe, PJ ;
Yang, JL ;
Berney, CR ;
Erskine, C ;
Ham, JM ;
Fisher, R ;
Russell, PJ .
WORLD JOURNAL OF SURGERY, 2001, 25 (08) :996-1001
[7]   The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas [J].
Cunningham, JM ;
Kim, CY ;
Christensen, ER ;
Tester, DJ ;
Parc, Y ;
Burgart, LJ ;
Halling, KC ;
McDonnell, SK ;
Schaid, DJ ;
Vockley, CW ;
Kubly, V ;
Nelson, H ;
Michels, VV ;
Thibodeau, SN .
AMERICAN JOURNAL OF HUMAN GENETICS, 2001, 69 (04) :780-790
[8]   Clinical relevance of transforming growth factor α, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors [J].
De Jong, KP ;
Stellema, R ;
Karrenbeld, A ;
Koudstaal, J ;
Gouw, ASH ;
Sluiter, WJ ;
Peeters, PMJG ;
Slooff, MJH ;
De Vries, EGE .
HEPATOLOGY, 1998, 28 (04) :971-979
[9]   Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer - Analysis of 1001 consecutive cases [J].
Fong, Y ;
Fortner, J ;
Sun, RL ;
Brennan, MF ;
Blumgart, LH .
ANNALS OF SURGERY, 1999, 230 (03) :309-318
[10]   Liver resection for colorectal metastases [J].
Fong, YM ;
Cohen, AM ;
Fortner, JG ;
Enker, WE ;
Turnbull, AD ;
Coit, DG ;
Marrero, AM ;
Prasad, M ;
Blumgart, LH ;
Brennan, MF .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (03) :938-946